Protagen launches first CE marked diagnostic assays Multilisa® CENP-B and Scl-70 for the diagnosis of Systemic Sclerosis

DORTMUND, Germany--()--Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the launch of its first CE marked diagnostic assays Multilisa® CENP-B and Multilisa® Scl-70 ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).

The Protagen Multilisa® SSc program combines novel and proprietary markers with existing diagnostic standards to help understand the condition at a molecular level. Multilisa® CENP-B and Multilisa® Scl-70 are intended for the semi-quantitative determination of IgG antibodies specific for the CENP-B and Scl-70 proteins. Analysis of autoantibodies against both proteins is part of the guidelines for the diagnosis and treatment of SSc patients. The presence of these autoantibodies in the serum of SSc patients is almost mutually exclusive and each antibody defines specific sub-forms of SSc. Together they are able to help in the diagnosis of around 70% of SSc patients.

SSc is a systemic autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. SSc is associated with the presence of several specific autoantibodies to intracellular targets which occur in around 80% of the SSc patients. As autoantibody specificities are strongly associated with patterns of organ involvement and disease outcome, they are an essential tool in the clinical management of SSc, an orphan disease with high mortality.

"With Multilisa® CENP-B and Multilisa® Scl-70, we present the first Protagen CE marked diagnostic assays in an easy to use ELISA format. We selected SSc for our first product development program due to the high medical and diagnostic need in this indication," said Dr. Stefan Müllner, CEO of Protagen. "These generic markers are part of the SSc guidelines and it is therefore necessary to include them in a comprehensive product offering. We will follow this launch with further proprietary markers to support physicians in their quest to significantly impact on and improve the management of SSc patients.”

About Protagen – Diagnostics Differentiated

Protagen AG, headquartered in Dortmund, Germany, specializes in the development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of autoimmune diseases.

Protagen uses its proprietary SeroTag® biomarker platform to identify disease specific autoantibodies and is on target to become the leading provider of autoimmune diagnostic products, specifically targeting diseases with an unmet need for effective diagnostics. With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen works to develop its own diagnostic pipeline, and partners with other organizations to develop and implement new companion diagnostic tools for better personalized treatment strategies.

For more information, please visit www.protagen.com

Contacts

Protagen AG
Dr. Georg Lautscham
CBO
Tel: +49-(0)-231-9742-6300
Fax: +49-(0)-231-9742-6301
E-Mail: bd@protagen.com
or
Media Enquiries
Dr. Clare Russell
Managing Director
BioStrata
T +44-1223-828200
M +44-7812-343412
crussell@biostratamarketing.com

Release Summary

Protagen AG today announced the launch of its first CE marked diagnostic assays to aid in the diagnosis of Systemic Sclerosis (SSc).

Contacts

Protagen AG
Dr. Georg Lautscham
CBO
Tel: +49-(0)-231-9742-6300
Fax: +49-(0)-231-9742-6301
E-Mail: bd@protagen.com
or
Media Enquiries
Dr. Clare Russell
Managing Director
BioStrata
T +44-1223-828200
M +44-7812-343412
crussell@biostratamarketing.com